Advaxis (ADXS) Earning Somewhat Positive Press Coverage, Report Finds

News headlines about Advaxis (NASDAQ:ADXS) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Advaxis earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.132159147912 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the news stories that may have effected Accern’s rankings:

Advaxis (ADXS) traded down 2.42% during midday trading on Friday, hitting $4.04. The company had a trading volume of 479,024 shares. The firm’s market capitalization is $165.90 million. Advaxis has a 52 week low of $3.90 and a 52 week high of $11.14. The firm’s 50 day moving average is $5.31 and its 200-day moving average is $6.85.

Advaxis (NASDAQ:ADXS) last posted its quarterly earnings results on Monday, September 11th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.27). Advaxis had a negative net margin of 655.66% and a negative return on equity of 93.54%. The business had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $3.43 million. On average, equities research analysts expect that Advaxis will post ($2.23) EPS for the current fiscal year.

A number of equities research analysts have weighed in on ADXS shares. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $19.00 target price on shares of Advaxis in a report on Monday, September 25th. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 target price on shares of Advaxis in a report on Friday, September 15th. BidaskClub raised Advaxis from a “hold” rating to a “buy” rating in a report on Saturday, September 9th. Finally, ValuEngine raised Advaxis from a “strong sell” rating to a “sell” rating in a report on Friday, September 8th.

COPYRIGHT VIOLATION NOTICE: “Advaxis (ADXS) Earning Somewhat Positive Press Coverage, Report Finds” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/10/13/advaxis-adxs-earning-somewhat-positive-press-coverage-report-finds.html.

In other Advaxis news, major shareholder Adage Capital Partners Gp, L.L sold 600,000 shares of the company’s stock in a transaction dated Wednesday, October 11th. The shares were sold at an average price of $4.30, for a total transaction of $2,580,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 7.21% of the company’s stock.

Advaxis Company Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Insider Buying and Selling by Quarter for Advaxis (NASDAQ:ADXS)

Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply